Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal pemetrexed + dexamethasone for leptomeningeal metastasis from lung adenocarcinoma (Phase II)
ChiCTR2100050621Phase 2Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoint: overall survival. Started Sep 2021; status: recruiting.
02
Drugs
pemetrexed
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100050621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050621.